Arlinda Lee
Stock Analyst at Canaccord Genuity
(2.27)
# 2,603
Out of 4,736 analysts
48
Total ratings
45.83%
Success rate
7.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arlinda Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $18 → $21 | $14.98 | +40.19% | 3 | Sep 7, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $20 → $10 | $0.49 | +1,943.74% | 3 | Apr 5, 2022 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $25 → $6 | $0.90 | +563.72% | 5 | Mar 16, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $45 → $36 | $57.52 | -37.41% | 3 | Mar 7, 2022 | |
| CELC Celcuity | Initiates: Buy | $50 | $11.21 | +346.03% | 1 | Oct 8, 2021 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $151 → $160 | $41.51 | +285.45% | 3 | Aug 16, 2021 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $36 → $40 | $13.56 | +194.99% | 3 | Jul 15, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $92 → $105 | $41.28 | +154.36% | 12 | Oct 29, 2020 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $23 → $27 | $55.94 | -51.73% | 3 | May 19, 2020 | |
| BPMC Blueprint Medicines | Maintains: Buy | $115 → $100 | $111.96 | -10.68% | 5 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.24 | +2,132.14% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $18 | $0.69 | +2,520.47% | 3 | Nov 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $264 → $288 | $4.60 | +6,160.87% | 2 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $160 | $1.29 | +12,303.10% | 1 | Mar 29, 2018 |
Delcath Systems
Sep 7, 2023
Maintains: Buy
Price Target: $18 → $21
Current: $14.98
Upside: +40.19%
X4 Pharmaceuticals
Apr 5, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $0.49
Upside: +1,943.74%
Nektar Therapeutics
Mar 16, 2022
Maintains: Buy
Price Target: $25 → $6
Current: $0.90
Upside: +563.72%
Rhythm Pharmaceuticals
Mar 7, 2022
Maintains: Buy
Price Target: $45 → $36
Current: $57.52
Upside: -37.41%
Celcuity
Oct 8, 2021
Initiates: Buy
Price Target: $50
Current: $11.21
Upside: +346.03%
CRISPR Therapeutics AG
Aug 16, 2021
Maintains: Buy
Price Target: $151 → $160
Current: $41.51
Upside: +285.45%
Bicycle Therapeutics
Jul 15, 2021
Maintains: Buy
Price Target: $36 → $40
Current: $13.56
Upside: +194.99%
Ultragenyx Pharmaceutical
Oct 29, 2020
Maintains: Buy
Price Target: $92 → $105
Current: $41.28
Upside: +154.36%
Halozyme Therapeutics
May 19, 2020
Maintains: Buy
Price Target: $23 → $27
Current: $55.94
Upside: -51.73%
Blueprint Medicines
Apr 30, 2020
Maintains: Buy
Price Target: $115 → $100
Current: $111.96
Upside: -10.68%
Feb 24, 2020
Initiates: Buy
Price Target: $50
Current: $2.24
Upside: +2,132.14%
Nov 5, 2019
Maintains: Buy
Price Target: $15 → $18
Current: $0.69
Upside: +2,520.47%
Aug 15, 2018
Maintains: Buy
Price Target: $264 → $288
Current: $4.60
Upside: +6,160.87%
Mar 29, 2018
Maintains: Buy
Price Target: $300 → $160
Current: $1.29
Upside: +12,303.10%